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ABSTRACT: Aims: To describe the prevalence and intensity of different
symptoms in relation to tobacco abstinence. To explore latent dimensions
between symptoms in smokers trying to quit.  Design: A cross sectional study
using a questionnaire to retrospectively assess symptoms over a period of 12
months.  Setting: Swedish telephone quitline, a nationwide free of charge service.
Participants: All 741 individuals who had called the quitline and signed up for
smoking cessation treatment between February 2000 to November 2001 and
reported to have been smoke free for at least 24 hours during the previous 12
month period from first contact.  Measurements: Assessments were made by
self-report, and abstinence was defined as “not a single puff of smoke during the
last week”. A factor analysis approach where individual items aggregate into
factors was used to explore the relationship between the different symptoms.
Findings: High intensity of symptoms related to unsuccessful quitting attempts
and included craving, irritability, apprehension/anxiety, difficulties concentrating,
restlessness, depression/ depressed mood, and insomnia. The factor loadings of all
17 symptoms resulted in three factors with factor 1, psychological being the most
important. High scores on this factor relates to unsuccessful quitting attempts.
Using Nicotine Replacement Therapy (NRT) for 5 weeks or longer, reduced
symptoms included in factor 1. The other two factors were factor 2 physiological
and factor 3 neurological.  Conclusions: Symptoms that are psychological and/or
neurological in nature are interrelated and appear to be the most significant
obstacles for successful quitting attempts in a population-based setting. These
symptoms may be successfully treated with NRT.
KEYWORDS: Smoking cessation, quit rate, factor analysis, withdrawal,
symptoms.
INTRODUCTION
Many who try to quit smoking
relapse within the first week [1, 2] and
90 percent who attempt to stop smoking
without support, relapse within one year
[3, 4]. Although most of our knowledge
stems from closely monitored clinical
drug trials, the understanding of why a
majority of attempts to stop smoking
fail, is incomplete.
One factor that may explain a failed
quit attempt is the smoker’s experience
of nicotine withdrawal. Early relapsing
smokers are thought to be more severely
dependent, and smokers unable to stay
quit have reported more severe
withdrawal symptoms [5, 6].
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Although studies have focused on
different symptoms and varying
definitions of severity, they are generally
consistent with the American Psychiatric
Association Diagnostic and the
Statistical Manual definition of nicotine
withdrawal DSM-IV [7]. Nicotine
withdrawal includes symptoms of
anxiety/apprehension, restlessness,
d i f f i c u l t y  c o n c e n t r a t i n g ,
depression/depressed mood, irritability,
sleepiness/drowsiness, and insomnia [7].
Despite omission from the DSM-IV,
craving is also a cardinal feature of
sudden abstinence from nicotine use.
We hypothesise that respondents
who are failed quitters in a telephone
quitline report more severe symptoms
compared with subjects who succeed in
stopping smoking. This should hold even
after controlling for potential
confounders including age, gender, and
use of nicotine replacement therapy
(NRT). We also hypothesise that
depression/depressed mood may be
associated with failure to remain
abstinent. The objective of this study
was to describe the prevalence and
intensity of different symptoms in
relation to tobacco abstinence in a group
of quitters calling a quitline. We also try
to explore if there is a correlation
between the different symptoms.
MATERIAL AND METHODS
Study population and setting
The study is based on a 12-month
follow-up comprising all 1131 smokers
who had called the Swedish quitline and
signed up for smoking cessation
treatment from February 2000 to
November 2001. A total of 741 people
(66%) reporting to have been abstinent
for a minimum of 24 hours to a
theoretical maximum of 12 months
during the follow-up period were
included in the study base. The same
study population was used for all
analyses.
The Swedish quitline [8, 9] is a
nationwide free of charge service that
operates 51 hours per week through
three to four telephone lines. All calls
are registered on computerised patient
records. All callers signing up for
smoking cessation support by returning a
registration form by mail are included.
Self reported point prevalence
abstinence at 12 months was defined as
“not a single puff of smoke during the
last week”.
Measures
A questionnaire identifying 17
symptoms was sent by mail to all
subjects 12-13 months after first contact
with the quitline. Assessed symptoms
are presented in Table 1 and nine
correspond to the Diagnostic and
Statistic Manual for Mental Disorders
DSM-III-R [10] /DSM – IV criteria [7].
Increased appetite and weight gain were
excluded because of the narrow time
window used. Physiological symptoms
not included in the DSM comprised
nightmares, dizziness, mouth ulcers,
sweating, muscular pain, cramps,
constipation and other stomach trouble.
The question used to assess
symptoms was: “Did you experience any
of the symptoms listed below when you
abstained from smoking? -Reply to this
question only if you have been abstinent
for at least 24 h since your first contact
with the quitline”.
For self-assessment of symptoms we
used: none, low, moderate, and high
[11]. One additional question was asked
to explore i f  those having
depression/depressed mood as a
symptom were more prone to relapse
“Have you been unusually stressed or
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depressed during any period after your
first contact with the quitline?”.
NRT use was assessed by asking the
question ”which of the following
nicotine replacement products did you
use after your first contact with the
quitline?”. Pharmacological treatment
included: chewing gum, transdermal
nicotine patch, inhaler, nasal spray or
tablets.
Ethical approval was obtained by
Karolinska Institutet (Dnr 00-367).
Statistical methods and presentation of
data
Logistic regression analysis was used
to calculate crude and adjusted odds
ratios with 95% confidence interval. To
analyse the relationship between
symptoms and abstinence we
dichotomised the response alternatives
(none, low, moderate, and high) into low
and high intensity. This was done so that
for each variable, the two categories
became as equally sized as possible. The
cut-offs for the assessment of NRT use
were “less than 5 weeks”, “5 weeks or
more”, or “not at all”. NRT was also
assessed as “NRT” vs. “no NRT use”.
Significance levels for all tests were
two-tailed. Statistical analysis was
carried out using the Statistical Package
for the Social sciences (SPSS 12.1).
A factor analysis approach where
individual items aggregate into factors
was used to explore the relationship
between the different symptoms. Firstly,
a principal component analysis was
conducted to explore the correlation
between the 17 symptoms. Secondly,
varimax orthogonal rotation was done to
simplify the interpretation of the factors
by maximising the variance of the
loadings within factors, across variables.
It was decided a priori that the number
of factors in the varimax rotation should
be based on the number of Eigenvalues
≥ 1,0 in the principal component
analysis and Cattell’s scree test was
performed [12, 13, 14]. Factor loadings
greater than 0.35 was a priori considered
to be of importance when interpreting
the factors.
A factor loading matrix is created
were correlations between factors and
variable are presented. The first column
is correlations between the first factor
and each variable in turn. The second
column is correlations between the
second factor and each variable in turn
and goes on the same way for the third
factor. A factor is interpreted from the
variables that are highly correlated with
it – that have high loadings on it [14].
To assess the relationship between
factors and abstinence, factor scores
were calculated using the regression
method and t-test was performed.
RESULTS
Prevalence of symptoms
Of the 1131 subjects who agreed to
participate in the study, 66% (741/1131)
reported  to have been smoke free for at
least 24 hours. Of those 741, fourteen
(2%) reported no symptoms (not in
table). The description of all symptoms
are given in Table 1. A total of 43%
reported to have high craving and 34%
reported high restlessness. Other
relevant symptoms were reported by
approximately one in four subjects:
apprehension/anxiety 25%, irritability
24%, difficulties concentrating 24%, and
depression/depressed mood 24% (Table
1).
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TABLE 1 Frequency and intensity of reported symptoms in smokers abstaining from
tobacco at least 24 hours. (N=741)
Symptoms  No
%        n
Low
%        n
Moderate
%        n
High
%        n
Craving 12%  (91) 15% (115) 29% (215) 43% (320)
Irritability 24% (177) 25% (185) 27% (203) 24% (176)
Apprehension/
Anxiety
27% (200) 24% (175) 25% (182) 25% (184)
Restlessness 18% (135) 21% (156) 27% (199) 34% (251)
Difficulties
concentrating
29% (216) 23% (168) 24% (181) 24% (176)
Depression/
depressed mood
35% (261) 20% (151) 21% (153) 24% (176)
Headache 61% (450) 18% (137) 13% (94)   8%   (60)
Insomnia 46% (341) 18% (137) 15% (111) 20% (152)
Sleepiness/drowsiness 61% (450) 17% (128) 12% (91) 10% (72)
Nightmares 71% (526/) 12% (89)   9% (64)   8% (62)
Dizziness 66% (493) 17% (130)   9% (64)   7% (54)
Mouth ulcers 81% (601)   7% (55)   5% (35)   7% (50)
Sweating 58% (429) 16% (119) 14% (107) 12% (86)
Muscular pain 76% (562) 12% (90)   6% (45)   6% (44)
Cramps 88% (650)   5% (41)   4% (27)   3% (23)
Constipation 70% (519) 12% (89)   8% (62) 10% (71)
Other stomach trouble 75% (558) 11% (85)   8% (56)   6% (42)
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Abstinence
Of all subjects 48% (354/741)
reported not a single puff of smoking
during the previous week (point
prevalence abstinence). There was no
significant difference regarding the
prevalence of symptoms when
comparing those being smoke free for at
least 24 hours with those being abstinent
for seven days, two months or six
months (not in table). The observed
relationship between symptoms and
abstinence remained even after
adjustment for age, gender, and use of
nicotine replacement therapy (not in
table).  Of those having depression/
depressed mood 28% (184/649) reported
abstinence compared with 72%
(465/649) not being abstinent OR (1.4 -
1.8).
NRT use
NRT was used by 80% (592/741). Of
those reporting NRT use 34% (199/592)
were smoke free compared to 27%
(121/446) of subjects reporting not
having used NRT, OR 1.4 (1.0-1.8), (not
in table). Of people using NRT for 5
weeks or longer 48% (115/237) reported
to be smoke free, compared to 27%
(121/446) in those who did not use NRT,
OR 2.5 (1.8-3.5), (not in table). When
the analysis was restricted to include
only people reporting having been
smoke free for at least 5 weeks, those
using NRT were less likely to be point-
prevalence smoke free 54% (171/317)
vs. 65% (121/186) OR 0.6 (0.4-0.9), (not
in table).
High intensity of symptoms related
to unsuccessful quitting attempts and
comprised craving, irritability,
apprehension/anxiety, difficulties
concentrating, restlessness, depression/
depressed mood and insomnia. A reverse
relation was observed for mouth ulcers
(Table 2).
Factor analysis
Three factors whose eigenvalues
(i.e., the sum of the squared factor
loadings) were greater than 1 were
identified and accounted for 49% of the
variance. Factor loading greater than
0.35 was considered in the interpretation
of the factors (Table 3). The greater the
loading, the more the variable is
considered a pure measure for the factor
[15]. Factor 1 (p s y c h o l o g i c a l )
comprised symptoms that were mainly
psychological and to some extent
neurological in nature. Assigned to this
group were craving, irritability,
apprehension/anxiety, difficulties
concentrating (also included in factor 3),
restlessness, and depression/ depressed
mood (also included in factor 3), (Table
3). Factor 2 (physiological) included
symptoms that were primarily physical
(somatic) and partly neurological
including mouth ulcers, dizziness, (also
included in factor 3) sweating, muscular
pain, cramps, constipation, and other
stomach trouble (Table 3). Factor 3
(neurological)  comprised mainly
symptoms that may be termed
neurological as well as some symptoms
that are more psychological in nature
including headache, insomnia,
sleepiness/drowsiness, nightmares,
dizziness, difficulties concentrating (also
included in factor 1), and depression/
depressed mood (also included in factor
1), (Table 3).
Factor scores and abstinence
The comparison between the mean
values of the factor scores revealed that
a high factor score on factor 1
(psychological) was significantly related
to unsuccessful quitting attempts.
Symptoms in smokers trying to quit 49
TABLE 2 Withdrawal symptoms versus abstinence. Presenting percentage and
proportion reporting to be abstinent. (N=741)
Symptoms Low intensity High
intensity(ref)
 OR  95%CI#
Craving 49% (207/421) 32% (103/320)    2.0  1.5-2.8*
Irritability 45% (163/362) 39% (147/379)    1.3  1.0-1.7*
Apprehension/
Anxiety
47% (177/375) 36% (133/366)    1.6  1.2-2.1*
Restlessness 49% (142/291) 37% (168/450)    1.6  1.2-2.2*
Difficulties
concentrating
46% (175/384) 38% (135/357)    1.4  1.0-1.8*
Depression/depressed
 mood
48% (196/412) 35% (114/329)    1.7  1.3-2.3*
Headache 40% (182/450) 44% (128/291)    0.9  0.6-1.2
Insomnia 45% (155/341) 39% (155/400)    1.3  1.0-1.8*
Sleepiness/drowsiness 41% (186/450) 43% (124/291)    0.9  0.7-1.3
Nightmares 42% (222/526) 41% (88/215)    1.1  0.8-1.5
Dizziness 42% (206/493) 42% (104/248)    1.0  0.7-1.4
Mouth ulcers 40% (238/601) 51% (72/140)    0.6  0.4-0.9*
Sweating 42% (180/429) 42% (130/312)    1.0  0.8-1.4
Muscular pain 41% (233/562) 43% (77/179)    0.9  0.7-1.3
Cramps 41% (269/650) 45% (41/91)    0.9  0.6-1.3
Constipation 43% (222/519) 40% (88/222)    1.1  0.8-1.6
Other stomach trouble 41% (227/558) 45% (83/183)    0.8  0.6-1.2
Note: Dichotomisation was done so that for each symptom, the two categories became as equally sized as
possible
* Difference statistically significant
# Crude odds ratios with 95% confidence interval
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TABLE 3 Factor analysis including items of distinctive groups, psychological,
physiological and neurological.
                                    Factor
1 2 3
Craving .701 .176 -.238
Irritability .714 .090 .175
Apprehension/anxiety .741 .045 .328
Restlessness .738 .085 .220
Difficulties concentrating .713 .085 .367
Depression/depressed mood .546 .046 .444
Headache .182 .192 .647
Insomnia .257 .195 .625
Sleepiness/drowsiness .136 .209 .633
Nightmares .155 .274 .576
Dizziness .107 .453 .432
Mouth ulcers .056 .583 .080
Sweating .209 .575 .317
Muscular pain .047 .693 .151
Cramps .053 .726 .017
Constipation .093 .533 .205
Other stomach trouble .037 .526 .276
Note: Factor loadings greater than 0.35 are boldface and constitute a relationship defining a factor
NRT and symptoms
When compared with those reporting not
having used nicotine replacement
therapy (NRT), using NRT for less than
5 weeks was significantly correlated
with an increased prevalence of craving,
irritability, difficulties concentrating and
mouth ulcers, and a decreased
prevalence of cramps (Table 4). With
exception of mouth ulcers these
correlations did not remain when
comparing non-users of NRT to users of
NRT for 5 weeks or longer. The
tendency of increased prevalence for
users of NRT for less than 5 weeks, but
not for users of NRT for 5 weeks or
longer, was seen for all symptoms
comprising the psychological factor
(Figure 1). Constipation and other
stomach trouble showed yet another
pattern with an increase of prevalence
for users of NRT for 5 weeks or longer
but not for users of NRT for less than 5
weeks (Table 4). Of all NRT users those
using chewing gum reported more
ulceration compared with those using
non-oral NRT, 24% (53/216) versus
18% (40/227), OR 1.5 (1.0-2.4) (not in
table).
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TABLE 4 How NRT is related to different symptoms N=625
Symptoms Ref No NRT#     NRT<5 weeks          NRT ≥5 weeks
Craving 36% (88/242) 53% (98/185)
2.0 (1.3-2.9)*
42% (83/198)
1,3 (0.9-1.9)
Irritability 48% (117/242) 60% (111/185)
1.6 (1.1-2.4)*
47% (94/198)
1.0 (0.7-1.4)
Apprehension/
anxiety
51% (123/242) 57% (106/185)
1.3 (0.9-1.9)
45% (89/198)
0.8 (0.5-1.2)
Restlessness 56% (136/242) 63% (116/185)
1.3 (0.9-1.9)
61% (120/198)
1.2 (0.8-1.8)
Difficulties concentrating
44% (107/242) 55% (101/185)
1.5 (1.0-2.2)*
46% (92/198)
1.1 (0.8-1.6)
Depression/depressed
mood
43% (103/242) 47% (87/185)
1.2 (0.8-1.8)
41% (82/198)
1.0 (0.7-1.4)
Headache 38% (91/242) 43% (80/185)
1.3 (0.9-1.9)
38% (76/198)
1.0 (0.7-1.5)
Insomnia 49% (118/242) 54% (99/185)
1.2 (0.8-1.8)
56% (111/198)
1.3 (0.9-2.0)
Sleepiness/drowsiness 39% (94/242) 41% (76/185)
1.1 (0.7-1.6)
39% (78/198)
1.0 (0.7-1.5)
Nightmares 28% (67/242) 27% (50/185)
1.0 (0.6-1.5)
32% (64/198)
1.2 (0.8-1.9)
Dizziness 35% (85/242) 35% (64185)
1.0 (0.7-1.5)
32% (64/198)
0.9 (0.6-1.3)
Mouth ulcers 15% (36/242) 22% (41/185)
1.6 (1.0-2.7)*
24% (47/198)
1.8 (1.1-2.9) *
Sweating 40% (96/242) 45% (83/185)
1.2 (0.8-1.8)
41% (82/198)
1.1 (0.7-1.6)
Muscular pain 26% (62/242) 23% (43/185)
0.9 (0.6-1.4)
23% (46/198)
0.9 (0.6-1.4)
Cramps 15% (35/242) 6% (11/185)
0.4 (0.2-0.8)*
15% (29/198)
1.0 (0.6-1.7)
Constipation 26% (62/242) 29% (53/185)
1.2 (0.8-1.8)
35% (69/198)
1.6 (1.0-2.3) *
Other stomach trouble 21% (52/242) 25% (47/185)
1.2 (0.8-1.9)
29% (58/198)
1.5 (1.0-2.3) *
Note: Dichotomisation was done so that for each symptom, the two categories became as equally sized as
possible
# Crude odds ratios with 95% confidence interval comparing with no NRT use
*Difference statistically significant
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Trend of withdrawal symptoms
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Figure 1 Symptoms in relation to NRT use. Presenting odds ratios for high intensity of
different symptoms in relation to NRT use.
DISCUSSION
Three factors of symptoms reported
to be related to tobacco abstinence were
identified among this group of
consecutive callers to the Swedish
quitline (Table 3): “psychological”
(factor 1), “physiological” (factor 2),
and “neurological”  (factor 3). The
symptoms that were most frequently
reported (Table 1) were the symptoms
comprising what we labelled as the
psychological factor. All symptoms
comprising the psychological factor
were statistically related to point
prevalence abstinence at 12 months, with
those reporting low intensity of the
symptoms being more likely to report
abstinence.
Symptoms and abstinence:  Al l
symptoms comprising the psychological
factor were negatively related to point
prevalence abstinence at 12 months. This
factor comprised largely the same
symptoms that have previously been
highlighted in the assessment of tobacco
cessation in other settings [16, 17] and
related to abstinence [18, 19, 20]. Three
prospective studies have reported
depression/depressed mood as being
predictive of unsuccessful smoking
cessation and relapse [21, 20, 22]. This
is in line with our results where having
depression/depressed mood as a
symptom proved to be associated with
failure to remain abstinent. Also in table
2 having high intensi ty of
depression/depressed mood related
negatively to abstinence. (Table 2).
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In our study, only two symptoms not
belonging to the psychological factor,
were related to abstinence: insomnia and
mouth ulcers. Insomnia included in the
neurological factor (factor 3) in Table 3
was one of three symptoms assessing
sleeping disorders that comprised half of
the symptoms in this factor. Studies of
nicotine withdrawal have consistently
found sleep disturbance to be a common
complaint [23] and since three of the
s y m p t o m s  i n s o m n i a ,
sleepiness/drowsiness and nightmares
related to sleep disturbance and had
relatively high factor loadings we might
have a latent dimension of sleeping
disorders in factor 3.
The other symptom not belonging to
the psychological factor,  and
significantly related to abstinence was
mouth ulcers, belonging to the
physiological factor (factor 2) in Table
3. In this case the relationship was
reverse. Subjects reporting mouth ulcers
were more likely to be abstinent. This
might be explained by the fact that NRT
use was positively related to mouth
ulcers. In our study, high intensity of
mouth ulcers was reported by 7%.
Another study found that 8% reported
severe mouth ulcers [24] in relation to
smoking cessation.
It has been reported that one in ten
patients has severe problems with
constipation in relation to smoking
cessation [25]. This was confirmed in
our results.
Symptoms and NRT:
 All  psychological symptoms
appeared to be associated with NRT use.
People using NRT for less then 5 weeks
reported a higher prevalence of these
symptoms compared with individuals
not using NRT and those who used NRT
for 5 weeks or longer.
It would be expected that people
experiencing low intensity of these
symptoms would be less prone to use
NRT. Figure 1 illustrates that people
using NRT to ease psychological
symptoms need taking higher doses to
achieve results. These findings are in
line with previous reports [26] and
present recommendations regarding
NRT [27]. There was a significant
increase of mouth ulcers in NRT users
compared with non-users. One
hypothesis is that this may be due to a
changed balance in oral microbial flora
secondary to the toxic effect of nicotine.
NRT and abstinence:
 The hypothesis that nicotine
withdrawal may be an important reason
why individuals persist in their smoking
behaviour and are relat ively
unsuccessful in their smoking cessation
attempts [28, 29] is supported by our
results. That can be seen by the
relationship between low prevalence of
symptoms comprising the psychological
factor, increased abstinence and the
suppressing effect of NRT use for 5
weeks or longer on these symptoms.
However, the relationship between
nicotine withdrawal and unsuccessful
smoking cessation has been ambiguous
in previous reviews of the literature [30].
One reason for this unclear relationship
may be insufficient control for
psychological and environmental factors
strongly related to abstinence [8]. These
psychological and environmental factors
will delude the relationship between
nicotine dependency and successful
cessation if not controlled for. Also, the
assessment of dependence usually
comprises questionnaires that should at
best be viewed as indicators of
dependence and are by no means
objective measures of a physiological
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phenomenon [31]. There is a possibility
of unidentified physiological factors of
dependence in tobacco that may partly
be responsible for the diffuse
relat ionship between nicot ine
withdrawal and unsuccessful smoking
cessation. However, such a hypothesis is
highly speculative. However, the risk of
experiencing nicotine withdrawal after a
quit attempt is known to be partly related
to genetic vulnerability [18].
Gender has been reported to
influence withdrawal discomfort [32].
However, other studies, including ours,
found no differences in overall
withdrawal severity between men and
women [17, 23, 32].
Methodological limitations:
 The present study assesses a
population of smokers having called a
quitline for smoking cessation support.
We do not know if those not
participating in the follow-up (30%) had
more withdrawal symptoms. However,
in a previously published study [33] we
assessed the behaviour of non-
responders by using telephone
interviews with a sample of people not
participating in the 12 months follow-up.
No significant difference regarding
abstinence rates between responders and
non-responders was found in our
material.
Another possible source of error
includes the use of single item measures
of symptoms, rating each symptom on a
four point prevalence intensity scale [34,
35]. An alternative would have been to
use validated psychometric scales to
assess the prevalence and intensity of
symptoms l ike  anxie ty  and
depression/depressed mood. This was
not deemed practical in the quitline
setting due to the large number of
patients.
As most smokers report multiple quit
attempts before they succeed [36] it is
plausible that individuals eventually
learn to endure the symptoms of
withdrawal. Thus, the reported
symptoms (Table 1) may be an
underestimation. Also, coping strategies
such as relaxation or seeking social
support which may have been achieved
through the quitline counsellors, may
have moderated symptom stress.
Another caveat in a retrospective study
is recall bias.
The questionnaire used by the
Swedish quitline at the time assessed
withdrawal symptoms only among
smokers who had made a serious attempt
to quit and had been totally tobacco free
for at least 24 hours. Thus, comparing
symptoms between smokers not
attempting to quit and those who were at
least temporary successful (24 hours or
more) was not possible. Further, we do
not know the prevalence and intensity of
the assessed symptoms in the general
population of non smokers. Thus,
baseline data on the prevalence of the
symptoms was not available which is a
problem for the presentation of symptom
prevalence in Table 1. However, this is
probably not a major problem for the
analysis of the relationship between
symptoms and to what extent the
reported symptoms were related to the
12 months abstinence rate.
It has been argued that a quit attempt
that lasted a week or longer in the last
year appears less biased by recall than
any attempt of a day or longer in the last
year [37]. However, the 24 hour time
frame of abstinence used for symptom
assessment was selected to achieve
better statistical power in the analysis. It
may be argued that the 24 hour time
window is too narrow but we argue that
this is justifiable since there was no
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significant difference detected regarding
prevalence of symptoms in the 24 hour
group when compared with people
reporting longer abstinence (seven days,
two and 6 months). It was noted [1] that
self-report ratings of behaviours and
internal states becomes less valid when
participants are asked to rate them over a
substantial period of time (i.e. 2-4
weeks) rather than a shorter time period
(i.e. within the past 24 hrs.).
Unfortunately only abstinent subjects
were examined since the question only
addressed those being abstinent for at
least 24 h. This may have understated
symptom severity.
NRT was measured only with a
question assessing duration of treatment
and the cut-offs were less than 5 weeks,
5 weeks or more, or not at all. There was
no measure of the intensity of the NRT
treatment during the assessed time
frame. This is likely to reduce the
sensitivity of assessment of the impact
NRT may have on the severity of the
symptoms.
Although the 17 symptoms measured
here fell almost cleanly into three
distinct groupings, this does not mean
that there are only three factors of
symptoms related to tobacco withdrawal.
There may be other factors not captured
by these 17 items. Additional studies
need to be done to further explore the
mechanisms that produce the three
factors observed in this study.
In conclusion, our results indicate
that high prevalence of symptoms
comprising the psychological factor
relate to unsuccessful quitting attempts
in a population-based setting. NRT
appeared to have a positive effect on
relieving these symptoms when used for
five weeks or more.
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